PROF

Profound Medical Corp.

$7.68

4.63%
SectorHealthcareIndustryMedical DevicesCountryCanada

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Source: Yahoo Finance
AI summary

Price & performance

1M+11.1%
3M-9.3%
YTD-17.6%
1Y+9.5%
52-week range—
Beta0.90
Full chart and returns against a benchmark

Q-Score

46/ 100

Quality against peers; 50 is the peer median.

Growth71
Risk56
Performance42
Valuation39
Profitability44
Leverage42
Sentiment73
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$16.1M+65.3%
Net income-$42.6M
Net margin-264.4%+21.1 pts
Historical fundamentals

Red flags in filings

1active red flag
Restated financialsMar 7, 2025
Filings, findings and the timeline

Revenue exposure

24%of revenue from outside the US
United States76%
Canada19%
Germany5%
Regions, segments, customers and suppliers

Valuation

PROFIndustryP/E—29.61P/S11.543.49EV/EBITDA—18.38P/B6.623.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate$-0.20
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate